C12N 2750/10071
Demonstrated in vivo effect
C12N2750/10071 (Demonstrated in vivo effect) appears on 31 US grants and 41 published applications in this corpus.
Search patents in C12N- Granted patents
- 31
- Published applications
- 41
- Assignees
- 19
- Inventors
- 66
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 2 | 1 |
| 2008 | 1 | 7 |
| 2009 | 0 | 2 |
| 2010 | 3 | 0 |
| 2011 | 2 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 0 |
| 2015 | 3 | 4 |
| 2016 | 0 | 5 |
| 2017 | 6 | 3 |
| 2018 | 6 | 2 |
| 2019 | 1 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 2 |
| 2022 | 1 | 0 |
| 2023 | 1 | 2 |
| 2024 | 1 | 1 |
| 2025 | 1 | 2 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Combination of vaccines to prophylactically treat a pig7 Apr 2026US 12,594,328 B2Intervet Inc.
- Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof7 Oct 2025US 12,433,942 B2
- Porcine Circovirus Type 3 (PCV3) vaccines, and production and uses thereof13 Feb 2024US 11,896,659 B2
- Porcine Circovirus Type 3 (PCV3) vaccines, and production and uses thereof18 Jul 2023US 11,701,419 B2
- Vaccine treatment and control infectious against viral pathogens utilizing heparan sulfate (HS) as cellular receptor15 Feb 2022US 11,246,839 B2Universidad De Chile
- Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof12 Mar 2026US 2026/0069672 A1Boehringer Ingelheim Vetmedica GmbH
- Live-attenuated sars-cov-2 vaccine23 Oct 2025US 2025/0325653 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Novel recombinant porcine circovirus type 2 protein and use thereof16 Jan 2025US 2025/0018022 A1Innovac Corporation
- Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof11 Jul 2024US 2024/0226264 A1Boehringer Ingelheim Vetmedica GmbH
- A combination of vaccines to prophylactically treat a pig26 Oct 2023US 2023/0338500 A1Intervet Inc.
Most cited
By later US patents
- Circovirus sequences associated with piglet weight loss disease (PWD)65US 7,223,407 B2Wyeth · 2007
- Circovirus sequences associated with piglet weight loss disease (PWD)61US 7,314,628 B2Wyeth · 2008
- Circovirus sequences associated with piglet weight loss disease (PWD)60US 7,258,865 B2Wyeth · 2007
- Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs42US 7,829,273 B2Boehringer Ingelheim Vetmedica GmbH · 2010
- Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs31US 7,838,213 B2Boehringer Ingelheim Vetmedica GmbH · 2010